PE20250741A1 - Compuestos como agonistas de glp-1r - Google Patents
Compuestos como agonistas de glp-1rInfo
- Publication number
- PE20250741A1 PE20250741A1 PE2024001844A PE2024001844A PE20250741A1 PE 20250741 A1 PE20250741 A1 PE 20250741A1 PE 2024001844 A PE2024001844 A PE 2024001844A PE 2024001844 A PE2024001844 A PE 2024001844A PE 20250741 A1 PE20250741 A1 PE 20250741A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- compounds
- glp
- hydrogen
- ring
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invencion proporciona unos compuestos de formula (0) que pueden usarse como agonistas de los receptores del peptido 1 similar al glucagon (GLP-1R), o sales aceptables desde un punto de vista farmaceutico de estos. En la formula (0), R13 es -C(O)OH, entre otros; X es N o CRx, donde Rx es hidrogeno, OH o alquilo de C1- C6; Y es N o CRy, donde Ry es hidrogeno, OH o alquilo de C1- C6; n es 0 o 1; Q se selecciona del grupo que consiste en -C(R7)(R8)- donde R7 y R8 son independientemente H, halogeno, o alquilo de C1-C6, -O-, entre otros; R1 es -C1-C6 alquileno, entre otros; R2 y R3 tomados juntos con los atomos de carbono a los que se acoplan forman un anillo cicloalquilo de C3-C4 opcionalmente sustituido; o R2 y Rx, tomados juntos con los atomos de carbono a los que se acoplan forman un anillo de cicloalquilo de C3-C5 opcionalmente sustituido, y R3 es hidrogeno, oxo, o alquilo de C1-C6; m es 0, 1, 2 o 3; R4 es oxo o alquilo de C1-C6; el anillo A es arilo de C6-C14, entre otros; L es un enlace, -O-, C1-C6 alquileno, entre otros; el anillo B es cicloalquilo de C3-C10, arilo de C6-C14, entre otros. Tambien se proporcionan composiciones farmaceuticas que contienen dichos compuestos, o sales aceptables desde un punto de vista farmaceuticos de estos; y las composiciones al igual que los compuestos permiten tratar o prevenir una enfermedad o una afeccion mediada por GLP-1R.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263313160P | 2022-02-23 | 2022-02-23 | |
| PCT/US2023/013700 WO2023164050A1 (en) | 2022-02-23 | 2023-02-23 | Compounds as glp-1r agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20250741A1 true PE20250741A1 (es) | 2025-03-13 |
Family
ID=85724628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2024001844A PE20250741A1 (es) | 2022-02-23 | 2023-02-23 | Compuestos como agonistas de glp-1r |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US12410163B2 (es) |
| EP (1) | EP4482577A1 (es) |
| JP (1) | JP2025508812A (es) |
| KR (1) | KR20240150488A (es) |
| CN (1) | CN119095843A (es) |
| AU (1) | AU2023224854A1 (es) |
| CA (1) | CA3252943A1 (es) |
| CL (1) | CL2024002499A1 (es) |
| CO (1) | CO2024012792A2 (es) |
| IL (1) | IL315151A (es) |
| MX (1) | MX2024010346A (es) |
| PE (1) | PE20250741A1 (es) |
| TW (1) | TW202346289A (es) |
| WO (1) | WO2023164050A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL4408840T3 (pl) | 2021-09-27 | 2025-12-22 | Terns Pharmaceuticals, Inc. | Kwasy benzoimidazolokarboksylowe jako agoniści glp-1r |
| WO2023076237A1 (en) | 2021-10-25 | 2023-05-04 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
| PE20250741A1 (es) | 2022-02-23 | 2025-03-13 | Terns Pharmaceuticals Inc | Compuestos como agonistas de glp-1r |
| WO2024206647A1 (en) * | 2023-03-29 | 2024-10-03 | Terns Pharmaceuticals, Inc. | Polymorphic forms and salts of a glp-1r agonist |
| KR20250166323A (ko) | 2023-04-07 | 2025-11-27 | 테른스 파마슈티칼스, 인크. | 간 장애 또는 심장대사 질환의 치료에 사용하기 위한 thr베타 효현제 및 glp-1r 효현제를 포함하는 조합 |
| WO2025057134A2 (en) | 2023-09-14 | 2025-03-20 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| US12291530B1 (en) | 2023-11-24 | 2025-05-06 | Ascletis Pharma (China) Co., Limited | GLP-1R agonist and therapeutic method thereof |
| WO2025158275A1 (en) | 2024-01-24 | 2025-07-31 | Pfizer Inc. | Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds |
| KR20250125490A (ko) * | 2024-02-14 | 2025-08-22 | 주식회사 종근당 | Glp-1 수용체 작용제 및 이의 용도 |
| WO2025189141A1 (en) | 2024-03-08 | 2025-09-12 | Annapurna Bio, Inc. | Methods for treating obesity and increasing weight loss |
Family Cites Families (117)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9305623D0 (en) | 1993-03-18 | 1993-05-05 | Merck Sharp & Dohme | Therapeutic agents |
| GB9305641D0 (en) | 1993-03-18 | 1993-05-05 | Merck Sharp & Dohme | Therapeutic agents |
| AU679045B2 (en) | 1993-03-18 | 1997-06-19 | Merck Sharp & Dohme Limited | Benzimidazole derivatives |
| US5763263A (en) | 1995-11-27 | 1998-06-09 | Dehlinger; Peter J. | Method and apparatus for producing position addressable combinatorial libraries |
| US6960589B2 (en) | 2001-03-09 | 2005-11-01 | Abbott Laboratories | Benzimidazoles that are useful in treating sexual dysfunction |
| ATE369854T1 (de) | 2001-10-19 | 2007-09-15 | Ortho Mcneil Pharm Inc | 2-phenyl benzimidazole und imidazo-[4,5]-pyridine als cds1/chk2-inhibitoren und adjuvantien in der chemotherapie oder strahlungstherapie zur behandlung von krebs |
| US20040127504A1 (en) | 2002-09-06 | 2004-07-01 | Cowart Marlon D. | Benzimidazoles that are useful in treating sexual dysfunction |
| EP1628970A2 (en) | 2003-04-30 | 2006-03-01 | The Institutes of Pharmaceutical Discovery, LLC | Heterocycle substituted carboxylic acids as inhibitors of protein tyrosine phosphatase-1b |
| EP2007752B1 (en) | 2006-03-31 | 2010-08-18 | Janssen Pharmaceutica NV | Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine h4 receptor |
| WO2008012623A1 (en) | 2006-07-25 | 2008-01-31 | Pfizer Products Inc. | Benzimidazolyl compounds as potentiators of mglur2 subtype of glutamate receptor |
| CN102574786A (zh) | 2009-04-02 | 2012-07-11 | 默克雪兰诺有限公司 | 二氢乳清酸脱氢酶抑制剂 |
| US8580807B2 (en) | 2009-04-03 | 2013-11-12 | Merck Sharp & Dohme Corp. | Bicyclic piperidine and piperazine derivatives as GPCR modulators for the treatment of obesity, diabetes and other metabolic disorders |
| WO2011143365A1 (en) | 2010-05-13 | 2011-11-17 | Amgen Inc. | Nitrogen heterocyclic compounds useful as pde10 inhibitors |
| RS60432B1 (sr) | 2012-07-01 | 2020-07-31 | Novo Nordisk As | Upotreba glp-1 peptida sa dugim dejstvom |
| WO2015166398A1 (en) | 2014-04-30 | 2015-11-05 | Aurigene Discovery Technologies Limited | 3h-imidazo[4,5-b]pyridine derivatives as dihydroorotate dehydrogenase inhibitors |
| JOP20190060A1 (ar) | 2016-09-26 | 2019-03-26 | Chugai Pharmaceutical Co Ltd | مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1 |
| LT3555064T (lt) | 2016-12-16 | 2023-01-10 | Pfizer Inc. | Glp-1 receptoriaus agonistai ir jų naudojimas |
| JP7461104B2 (ja) | 2017-11-29 | 2024-04-03 | 中外製薬株式会社 | Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物 |
| US10934279B2 (en) | 2018-06-13 | 2021-03-02 | Pfizer Inc. | GLP-1 receptor agonists and uses thereof |
| WO2019239371A1 (en) | 2018-06-15 | 2019-12-19 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
| TWI705820B (zh) | 2018-06-22 | 2020-10-01 | 美商美國禮來大藥廠 | Gip/glp1促效劑組合物 |
| CR20210110A (es) | 2018-08-31 | 2021-05-13 | Pfizer | Combinaciones para tratamiento de ehna/ehgna y enfermedades relacionadas |
| IL283322B2 (en) | 2018-11-22 | 2025-08-01 | Qilu Regor Therapeutics Inc | GLP-1R agonists and their uses |
| CN113853371B (zh) | 2019-04-12 | 2024-05-03 | 上海齐鲁锐格医药研发有限公司 | Glp-1r激动剂及其用途 |
| TWI751585B (zh) | 2019-06-28 | 2022-01-01 | 美商美國禮來大藥廠 | 類升糖素肽1受體促效劑 |
| WO2021018023A1 (zh) | 2019-08-01 | 2021-02-04 | 济南泰达领创医药技术有限公司 | 小分子glp-1受体调节剂 |
| MX2022004874A (es) | 2019-10-25 | 2022-05-13 | Gilead Sciences Inc | Compuestos de modulacion de glp-1r. |
| UY38958A (es) | 2019-11-15 | 2021-05-31 | Ildong Pharmaceutical Co Ltd | Agonista del receptor glp-1 y uso de este |
| KR20210059584A (ko) | 2019-11-15 | 2021-05-25 | 일동제약(주) | Glp-1 수용체 작용제 및 이의 용도 |
| ES3010351T3 (en) | 2019-12-02 | 2025-04-02 | Hyundai Pharm Co Ltd | Glp-1 receptor agonist |
| JP2021091683A (ja) | 2019-12-10 | 2021-06-17 | ファイザー・インク | ２−（（４−（（Ｓ）−２−（５−クロロピリジン−２−イル）−２−メチルベンゾ［ｄ］［１，３］ジオキソール−４−イル）ピペリジン−１−イル）メチル）−１−（（（Ｓ）−オキセタン−２−イル）メチル）−１Ｈ−ベンゾ［ｄ］イミダゾール−６−カルボン酸の１，３−ジヒドロキシ−２−（ヒドロキシメチル）プロパン−２−アミン塩の固体形態 |
| EP4097097B1 (en) | 2020-01-29 | 2025-01-15 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| MX2022009524A (es) | 2020-02-07 | 2023-01-11 | Gasherbrum Bio Inc | Agonistas heterociclicos de glp-1. |
| CN115697999A (zh) | 2020-02-13 | 2023-02-03 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
| US20230203021A1 (en) | 2020-03-18 | 2023-06-29 | Lg Chem, Ltd. | Glp-1 receptor agonist, pharmaceutical composition comprising same, and method for preparing same |
| CN113493447B (zh) | 2020-04-03 | 2024-06-11 | 轩竹(北京)医药科技有限公司 | Glp-1受体激动剂 |
| TW202144340A (zh) | 2020-04-03 | 2021-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用 |
| US20230295154A1 (en) | 2020-04-29 | 2023-09-21 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| JP7702973B2 (ja) | 2020-05-27 | 2025-07-04 | キル・レガー・セラピューティクス・インコーポレーテッド | Ｇｌｐ－１ｒアゴニストの塩及び結晶形態、並びにそれらの使用 |
| JP7359974B2 (ja) | 2020-06-04 | 2023-10-11 | ハンチョウ サイウィンド バイオサイエンスィズ カンパニー リミテッド | 五員環ヘテロ芳香族イミダゾール系化合物及びその使用 |
| CN111548311B (zh) | 2020-06-04 | 2021-04-23 | 山西医科大学 | 一种小分子glp-1r激动剂及其应用 |
| US20230234968A1 (en) * | 2020-06-10 | 2023-07-27 | Medshine Discovery Inc. | Methyl-substituted benzobisoxazole compound and use thereof |
| CN115916772B (zh) | 2020-06-19 | 2025-01-14 | 江苏恒瑞医药股份有限公司 | 6-氧代-3,6-二氢吡啶类衍生物、其制备方法及其在医药上的应用 |
| CN113831337B (zh) | 2020-06-24 | 2023-03-24 | 广州市恒诺康医药科技有限公司 | Glp-1受体激动剂及其药物组合物和用途 |
| CA3186217A1 (en) | 2020-07-20 | 2022-01-27 | Eccogene (Shanghai) Co., Ltd. | Tetrahydropyrazolo-pyrazinyl-dihydroimidazolone or tetrahydropyrazolo-pyridinyl-dihydroimidazolone compounds and methods of using same |
| WO2022028572A1 (en) | 2020-08-06 | 2022-02-10 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| TW202214622A (zh) | 2020-08-06 | 2022-04-16 | 大陸商上海齊魯銳格醫藥研發有限公司 | Ｇｌｐ－１ｒ促效劑及其用途 |
| BR112023003168A2 (pt) | 2020-08-21 | 2023-05-09 | Terns Pharmaceuticals Inc | Compostos como agonistas do glp-1r |
| EP4204415A4 (en) | 2020-08-28 | 2025-03-26 | Gasherbrum Bio, Inc. | HETEROCYCLIC GLP-1 AGONISTS |
| CN119930604A (zh) | 2020-09-01 | 2025-05-06 | 江苏恒瑞医药股份有限公司 | 稠合咪唑类衍生物、其制备方法及其在医药上的应用 |
| CN116615430A (zh) | 2020-09-07 | 2023-08-18 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
| CN116368140A (zh) | 2020-09-10 | 2023-06-30 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
| WO2022068772A1 (zh) | 2020-09-29 | 2022-04-07 | 深圳信立泰药业股份有限公司 | 一种苯并咪唑类衍生物及其制备方法和医药用途 |
| CN116348464A (zh) | 2020-10-12 | 2023-06-27 | 杭州中美华东制药有限公司 | 苯并咪唑酮类glp-1受体激动剂及其用途 |
| EP4229049A4 (en) | 2020-10-13 | 2024-12-18 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| JP2023546055A (ja) | 2020-10-13 | 2023-11-01 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環ｇｌｐ－１アゴニスト |
| CA3195264A1 (en) | 2020-10-14 | 2022-04-21 | Wenge Zhong | Crystal forms of glp-1r agonists and uses thereof |
| US11851419B2 (en) | 2020-11-20 | 2023-12-26 | Gilead Sciences, Inc. | GLP-1R modulating compounds |
| WO2022111624A1 (zh) | 2020-11-27 | 2022-06-02 | 深圳信立泰药业股份有限公司 | 一种苯并咪唑类衍生物及其制备方法和医药用途 |
| CN114591308B (zh) | 2020-12-03 | 2024-03-08 | 苏州闻泰医药科技有限公司 | 一类glp-1r受体激动剂化合物及其用途 |
| JP2024500949A (ja) | 2020-12-25 | 2024-01-10 | 四川海思科制▲薬▼有限公司 | ５員環誘導体及びその医学的使用 |
| CR20230330A (es) | 2021-01-28 | 2023-11-15 | Carmot Therapeutics Inc | Agonistas del receptor gpcr, composiciones farmaceuticas que los comprenden y métodos para su uso |
| EP4304712A1 (en) | 2021-03-11 | 2024-01-17 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| WO2022192428A1 (en) | 2021-03-11 | 2022-09-15 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| WO2022199458A1 (zh) | 2021-03-22 | 2022-09-29 | 杭州中美华东制药有限公司 | 噻吩类glp-1受体激动剂及其用途 |
| EP4313963A1 (en) | 2021-03-24 | 2024-02-07 | Eccogene Inc. | Phenyl- [1, 3] dioxolo [4, 5-c] pyridinyl-phenyl-, phenyl- [1, 3] dioxolo [4, 5-c] pyridinyl-heteroaryl-, or phenyl- [1, 3] dioxolo [4, 5-c] pyridinyl-piperidinyl-methyl-oxetanylmethyl-1h-benzo [d] imidazole-carboxylic acid derivatives and methods of using same |
| US20240217966A1 (en) | 2021-03-24 | 2024-07-04 | Shionogi & Co., Ltd. | Pharmaceutical composition containing glp-1 receptor agonist having fused ring |
| ES2925124B2 (es) | 2021-03-29 | 2024-04-08 | Fundacion Univ San Antonio | Tratamiento de la obesidad |
| US20240300928A1 (en) | 2021-04-08 | 2024-09-12 | Lg Chem, Ltd. | Glp-1 receptor agonist, pharmaceutical composition comprising same, and method for preparing same |
| WO2022219495A1 (en) | 2021-04-12 | 2022-10-20 | Novartis Ag | 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity |
| MX2023012418A (es) | 2021-04-21 | 2023-10-31 | Gilead Sciences Inc | Compuestos de modulacion de glp-1r de carboxi-bencimidazol. |
| CN117177970A (zh) | 2021-04-30 | 2023-12-05 | 上海翰森生物医药科技有限公司 | 多环类衍生物调节剂、其制备方法和应用 |
| CA3217720A1 (en) | 2021-05-03 | 2022-11-10 | Xiaohui Du | Benzimidazoyl glp-1 receptor agonists, pharmaceutical compositions comprising the same, and methods for their use |
| TWI843104B (zh) | 2021-05-20 | 2024-05-21 | 美商美國禮來大藥廠 | 類升糖素肽1受體促效劑 |
| AU2022289247A1 (en) | 2021-06-10 | 2023-12-21 | Antag Therapeutics Aps | Treatment of obesity and obesity-related disorders |
| CA3219984A1 (en) | 2021-06-24 | 2022-12-29 | Wenqiang ZHAI | Glp-1 receptor agonist and composition and use thereof |
| CN117715906A (zh) | 2021-07-21 | 2024-03-15 | 和博医药有限公司 | 胰高血糖素样肽-1受体调节剂及其用途 |
| CN113480534B (zh) | 2021-07-23 | 2022-05-13 | 广州必贝特医药股份有限公司 | 苯并咪唑或氮杂苯并咪唑-6-羧酸类化合物及其应用 |
| CN117751110A (zh) | 2021-08-04 | 2024-03-22 | 上海翰森生物医药科技有限公司 | 环烯类衍生物调节剂、其制备方法和应用 |
| US20240366639A1 (en) | 2021-08-12 | 2024-11-07 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| CA3229355A1 (en) | 2021-08-27 | 2023-03-02 | Lloyd Berl KLICKSTEIN | Combination therapies |
| MX2024002503A (es) | 2021-08-30 | 2024-03-15 | Mindrank Ai Ltd | Nuevo compuesto heterociclico sustituido con aril eter como agonista de glp1r. |
| KR20240054335A (ko) | 2021-08-31 | 2024-04-25 | 화이자 인코포레이티드 | 2-[(4-｛6-[(4-시아노-2-플루오로벤질)옥시]피리딘-2-일｝피페리딘-1-일)메틸]-1-[(2s)-옥세탄-2-일메틸]-1h-벤즈이미다졸-6-카르복실산,1,3-디히드록시-2-(히드록시메틸)프로판-2-아민 염의 고체 형태 |
| US20240374587A1 (en) | 2021-09-08 | 2024-11-14 | Shionogi & Co., Ltd. | Medicine for prevention and treatment of diseases linked to anti-obesity activity |
| PL4408840T3 (pl) | 2021-09-27 | 2025-12-22 | Terns Pharmaceuticals, Inc. | Kwasy benzoimidazolokarboksylowe jako agoniści glp-1r |
| WO2023057429A1 (en) * | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators |
| WO2023057414A1 (en) * | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators |
| JP2024536353A (ja) | 2021-10-05 | 2024-10-04 | アストラゼネカ・アクチエボラーグ | Ｇｌｐ－１受容体修飾因子と特定の２，５－ジアザビシクロ［４．２．０］オクタン |
| TWI843243B (zh) | 2021-10-22 | 2024-05-21 | 大陸商盛世泰科生物醫藥技術（蘇州）股份有限公司 | 作為glp-1受體激動劑的化合物、包含其的藥物組成物及其用途 |
| WO2023076237A1 (en) | 2021-10-25 | 2023-05-04 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
| JPWO2023106310A1 (es) | 2021-12-07 | 2023-06-15 | ||
| CN114280573B (zh) | 2021-12-09 | 2025-09-26 | 上海禾赛科技有限公司 | 激光雷达及其测量目标反射率的方法和系统 |
| WO2023111145A1 (en) | 2021-12-16 | 2023-06-22 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| WO2023111144A1 (en) | 2021-12-16 | 2023-06-22 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| CN118434745A (zh) | 2021-12-29 | 2024-08-02 | 西藏海思科制药有限公司 | 一种glp-1激动剂的盐及其晶型和在医药上的应用 |
| JP2025504508A (ja) | 2022-01-24 | 2025-02-12 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環式ｇｌｐ－１アゴニスト |
| WO2023151575A1 (en) | 2022-02-09 | 2023-08-17 | Gasherbrum Bio Inc. | Heterocyclic glp-1 agonists |
| EP4476216A4 (en) | 2022-02-09 | 2025-12-03 | Gasherbrum Bio Inc | GLP-1 HETEROCYCLIC AGONISTS |
| JP2025505198A (ja) | 2022-02-10 | 2025-02-21 | ノバルティス アーゲー | 肥満の治療のためのｇｌｐ１受容体の活性化因子としての２－（（４－（（ｓ）－２－（４－クロロ－２－フルオロフェニル）－２－メチルベンゾ［ｄ］［１，３］ジオキソール－４－イル）ピペリジン－１－イル）メチル）－１－（（（ｓ）－オキセタン－２－イル）メチル）－１ｈ－イミダゾール誘導体 |
| PE20250741A1 (es) | 2022-02-23 | 2025-03-13 | Terns Pharmaceuticals Inc | Compuestos como agonistas de glp-1r |
| WO2023164358A1 (en) | 2022-02-28 | 2023-08-31 | Ascletis Bioscience Co., Ltd. | Glp-1r modulating compounds |
| JP2025509281A (ja) | 2022-03-09 | 2025-04-11 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環式ｇｌｐ－１アゴニスト |
| JP2025510741A (ja) | 2022-03-21 | 2025-04-15 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環式ｇｌｐ－１アゴニスト |
| EP4508047A1 (en) | 2022-04-14 | 2025-02-19 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| JP7809218B2 (ja) | 2022-05-20 | 2026-01-30 | 成都地奥九泓製薬廠 | ベンズイミダゾールまたはアザベンズイミダゾール化合物、その調製方法およびその使用 |
| CN114716423A (zh) | 2022-05-20 | 2022-07-08 | 中国科学院上海药物研究所 | 5,6-二氢-1,2,4-三嗪类化合物及其作为glp-1受体激动剂的药学用途 |
| WO2024041609A1 (zh) | 2022-08-24 | 2024-02-29 | 广州市联瑞制药有限公司 | 苯并双环类化合物及其制备方法和应用 |
| WO2024046342A1 (zh) | 2022-08-30 | 2024-03-07 | 广州市联瑞制药有限公司 | 苯并双环类化合物及其制备方法和应用 |
| WO2024051700A1 (zh) | 2022-09-05 | 2024-03-14 | 德睿智药(苏州)新药研发有限公司 | 作为glp1r激动剂的新型芳基氘代苄醚取代杂环类化合物 |
| JPWO2024063140A1 (es) | 2022-09-22 | 2024-03-28 | ||
| EP4592285A1 (en) | 2022-09-22 | 2025-07-30 | Shionogi & Co., Ltd. | Fused ring compound having glp-1 receptor agonist effect |
| AU2023377707A1 (en) | 2022-11-11 | 2025-05-15 | Eli Lilly And Company | Glucagon-like peptide 1 receptor agonists |
| CR20250178A (es) | 2022-11-16 | 2025-06-06 | Lilly Co Eli | Agonistas del receptor del péptido-1 similar al glucagón |
| WO2024131869A1 (en) | 2022-12-22 | 2024-06-27 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| WO2024149080A1 (zh) | 2023-01-13 | 2024-07-18 | 中国科学院上海药物研究所 | 用作glp-1受体激动剂的4-烷氧基苯并咪唑-6-羧酸衍生物 |
| TW202444350A (zh) | 2023-03-29 | 2024-11-16 | 美商拓臻製藥公司 | 作為ｇｌｐ—１ｒ激動劑之化合物 |
| WO2024206647A1 (en) | 2023-03-29 | 2024-10-03 | Terns Pharmaceuticals, Inc. | Polymorphic forms and salts of a glp-1r agonist |
-
2023
- 2023-02-23 PE PE2024001844A patent/PE20250741A1/es unknown
- 2023-02-23 TW TW112106805A patent/TW202346289A/zh unknown
- 2023-02-23 IL IL315151A patent/IL315151A/en unknown
- 2023-02-23 CN CN202380033881.4A patent/CN119095843A/zh active Pending
- 2023-02-23 AU AU2023224854A patent/AU2023224854A1/en active Pending
- 2023-02-23 CA CA3252943A patent/CA3252943A1/en active Pending
- 2023-02-23 US US18/173,426 patent/US12410163B2/en active Active
- 2023-02-23 JP JP2024549694A patent/JP2025508812A/ja active Pending
- 2023-02-23 MX MX2024010346A patent/MX2024010346A/es unknown
- 2023-02-23 KR KR1020247031110A patent/KR20240150488A/ko active Pending
- 2023-02-23 WO PCT/US2023/013700 patent/WO2023164050A1/en not_active Ceased
- 2023-02-23 EP EP23712657.8A patent/EP4482577A1/en active Pending
-
2024
- 2024-08-21 CL CL2024002499A patent/CL2024002499A1/es unknown
- 2024-09-20 CO CONC2024/0012792A patent/CO2024012792A2/es unknown
-
2025
- 2025-06-18 US US19/242,909 patent/US20260015348A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024010346A (es) | 2024-08-30 |
| TW202346289A (zh) | 2023-12-01 |
| AU2023224854A1 (en) | 2024-10-03 |
| US12410163B2 (en) | 2025-09-09 |
| US20260015348A1 (en) | 2026-01-15 |
| CA3252943A1 (en) | 2023-08-31 |
| KR20240150488A (ko) | 2024-10-15 |
| CL2024002499A1 (es) | 2025-01-24 |
| CO2024012792A2 (es) | 2024-12-19 |
| CN119095843A (zh) | 2024-12-06 |
| US20230322758A1 (en) | 2023-10-12 |
| WO2023164050A1 (en) | 2023-08-31 |
| IL315151A (en) | 2024-10-01 |
| EP4482577A1 (en) | 2025-01-01 |
| JP2025508812A (ja) | 2025-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20250741A1 (es) | Compuestos como agonistas de glp-1r | |
| PE20231206A1 (es) | Compuestos como agonistas de glp-1r | |
| PE20220931A1 (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina | |
| PE20211655A1 (es) | Compuestos de 6-azabencimidazol sustituidos como inhibidores de hpk1 | |
| PE20240886A1 (es) | Compuestos espirociclicos | |
| PE20240879A1 (es) | Inhibidor sos1 y uso del mismo | |
| CL2018002358A1 (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
| UY40470A (es) | Compuestos tricíclicos y sus usos | |
| AR063101A1 (es) | Derivados de pirazina-2-carboxiamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento o profilaxis de enfermedades asociadas con la modulacion de receptores del cb2. | |
| PE20040840A1 (es) | Derivados de 4-oxoquinolina como inhibidores de la integrasa del vih | |
| AR044399A1 (es) | Compuestos heterociclicos y su uso como activadores de receptores de ppar. composiciones farmaceuticas que los contienen | |
| AR062360A1 (es) | Derivados heterociclicos que modulan la actividad de la estearoil-coa-desaturasa | |
| AR077267A1 (es) | Derivados nitrogenados heterociclicos inhibidores selectivos de pi3k, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades inflamatorias y/o autoinmunes. | |
| PE20020592A1 (es) | Quinolonas como agentes antimicrobianos | |
| AR073622A1 (es) | Compuestos de benzo[d]isoxazol moduladores de receptores de dopamina d3 y de la serotonina 5-ht2a, proceso para prepararlos, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento de trastornos psicoticos | |
| PE20050013A1 (es) | Composiciones farmaceuticas como inhibidores de la proteasa del virus de la hepatitis c | |
| AR041055A1 (es) | Derivados de benzoimidazol utiles como agentes antiproliferativos, composicion farmaceautica en base al compuesto y un procedimiento de preparacion del compuesto | |
| PE20231297A1 (es) | Compuestos de piridotriazina sustituidos y usos de estos | |
| PE20210477A1 (es) | Derivado policiclico de carbamoilpiridona | |
| PE20191784A1 (es) | Compuestos inhibidores de vmat2, composiciones y metodos relativos a los mismos | |
| ECSP22093794A (es) | Compuestos espiro como antagonistas del receptor de melanocortina 4 y usos de los mismos | |
| PE20190964A1 (es) | Inhibidores de dopamina-b-hidroxilasa penetrantes de la barrera hematoencefalica | |
| UY29312A1 (es) | Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones | |
| PE20201068A1 (es) | Compuestos de pirazol sustituidos con heteroarilo y uso farmaceutico de los mismos | |
| PE20220252A1 (es) | Compuestos de pirrol |